These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
918 related articles for article (PubMed ID: 17593024)
1. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024 [TBL] [Abstract][Full Text] [Related]
2. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187 [TBL] [Abstract][Full Text] [Related]
3. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
4. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045 [TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652 [TBL] [Abstract][Full Text] [Related]
7. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M; Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205 [TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH; Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Jagannath S; Durie BG; Wolf J; Camacho E; Irwin D; Lutzky J; McKinley M; Gabayan E; Mazumder A; Schenkein D; Crowley J Br J Haematol; 2005 Jun; 129(6):776-83. PubMed ID: 15953004 [TBL] [Abstract][Full Text] [Related]
19. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191 [TBL] [Abstract][Full Text] [Related]
20. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Palumbo A; Attal M; Roussel M Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]